Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)

Simple item page
dc.contributor.authorEl-Hasbani, Georges
dc.contributor.authorJawad, Ali S.M.
dc.contributor.authorUthman, Imad W.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Allergy, Immunology and Rheumatology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:54:47Z
dc.date.available2025-01-24T11:54:47Z
dc.date.issued2019
dc.description.abstractBackground: Familial Mediterranean Fever (FMF), an autoinflammatory disease, is characterized by self-limited inflammatory attacks of fever and polyserositis along with high acute phase response. Although colchicine remains the mainstay in treatment, intolerance and resistance in a certain portion of patients have been posing a problem for physicians. Main body: Like many autoimmune and autoinflammatory diseases, many colchicine-resistant or intolerant FMF cases have been successfully treated with biologics. In addition, many studies have tested the efficacy of biologics in treating FMF manifestations. Conclusion: Since carriers of FMF show significantly elevated levels of serum TNF alpha, IL-1, and IL-6, FMF patients who failed colchicine were successfully treated with anti IL-1, anti IL-6, or TNF inhibitors drugs. It is best to use colchicine in combination with biologics. © 2019 The Author(s).
dc.identifier.doihttps://doi.org/10.1186/s13023-019-1201-7
dc.identifier.eid2-s2.0-85073435475
dc.identifier.pmid31615541
dc.identifier.urihttp://hdl.handle.net/10938/31174
dc.language.isoen
dc.publisherBioMed Central Ltd.
dc.relation.ispartofOrphanet Journal of Rare Diseases
dc.sourceScopus
dc.subjectAutoinflammatory diseases
dc.subjectBiologics
dc.subjectColchicine resistance
dc.subjectFamilial mediterranean fever
dc.subjectAnimals
dc.subjectColchicine
dc.subjectHumans
dc.subjectInterleukin-1
dc.subjectInterleukin-6
dc.subjectTumor necrosis factor-alpha
dc.subjectAdalimumab
dc.subjectAnakinra
dc.subjectCanakinumab
dc.subjectCorticosteroid
dc.subjectEtanercept
dc.subjectHydroxychloroquine
dc.subjectInfliximab
dc.subjectInterleukin 1
dc.subjectInterleukin 6
dc.subjectLeflunomide
dc.subjectMethotrexate
dc.subjectMycophenolic acid
dc.subjectPlacebo
dc.subjectPrednisolone
dc.subjectPrednisone
dc.subjectPyrin
dc.subjectRilonacept
dc.subjectSalazosulfapyridine
dc.subjectSteroid
dc.subjectTocilizumab
dc.subjectTofacitinib
dc.subjectTumor necrosis factor
dc.subjectAllergy
dc.subjectAlopecia
dc.subjectAmyloidosis
dc.subjectAutoimmune disease
dc.subjectAzoospermia
dc.subjectChronic arthritis
dc.subjectCinca syndrome
dc.subjectDiarrhea
dc.subjectDrug dose reduction
dc.subjectDrug efficacy
dc.subjectDrug megadose
dc.subjectDrug safety
dc.subjectDrug substitution
dc.subjectDrug withdrawal
dc.subjectFamilial cold autoinflammatory syndrome
dc.subjectGastrointestinal symptom
dc.subjectGene mutation
dc.subjectHeterozygote
dc.subjectHuman
dc.subjectInjection site pain
dc.subjectInjection site reaction
dc.subjectJuvenile rheumatoid arthritis
dc.subjectLow drug dose
dc.subjectMaximum tolerated dose
dc.subjectMefv gene
dc.subjectMuckle wells syndrome
dc.subjectPathogenesis
dc.subjectPatient compliance
dc.subjectProteinuria
dc.subjectRelapse
dc.subjectRemission
dc.subjectRespiratory tract infection
dc.subjectReview
dc.subjectRheumatoid arthritis
dc.subjectSystemic lupus erythematosus
dc.subjectUrinary tract infection
dc.subjectViral gastroenteritis
dc.subjectAnimal
dc.subjectBlood
dc.titleUpdate on the management of colchicine resistant Familial Mediterranean Fever (FMF)
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2019-7265.pdf
Size:
627.44 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine